New Perspectives on Antimicrobial Agents: Imipenem-Relebactam

Evolution of imipenem-relebactam resistance following treatment of multidrug-resistant Pseudomonas aeruginosa pneumonia

(2022) Ryan K Shields et al.   CLINICAL INFECTIOUS DISEASES

In vitro activity of imipenem-relebactam against KPC-producing Klebsiella pneumoniae resistant to ceftazidime-avibactam and/or meropenem-vaborbactam

(2022) Donatella Lombardo et al.   CLINICAL MICROBIOLOGY AND INFECTION

Co-resistance to ceftazidime-avibactam and cefiderocol in clinical isolates producing KPC variants

(2022) Laurent Poirel et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

In vitro activity of imipenem/relebactam plus aztreonam against metallo-β-lactamase-producing, OprD-deficient Pseudomonas aeruginosa with varying levels of Pseudomonas-derived cephalosporinase production

(2022) J. Nicholas O'Donnell et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-β-lactamase-producing Klebsiella pneumoniae

(2021) Sofia Maraki et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Activity of imipenem/relebactam against a Spanish nationwide collection of carbapenemase-producing Enterobacterales

(2021) Juan Carlos Vázquez-Ucha et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Activities of imipenem-relebactam combination against carbapenem-nonsusceptible Enterobacteriaceae in Taiwan

(2021) Tsung-Ying Yang et al.   JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION

In Vitro Susceptibility of Multidrug-Resistant Pseudomonas aeruginosa following Treatment-Emergent Resistance to Ceftolozane-Tazobactam

(2021) Abigail M. Rubio et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of Imipenem/Relebactam and Comparators Against Gram-Negative Pathogens from Patients with Bloodstream Infections in the United States and Canada – SMART 2018-2019

(2021) Sibylle H. Lob et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

In vitro activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan

(2021) Shu-Chen Kuo et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In vitro activity of cefepime/zidebactam (WCK 5222) against recent Gram-negative isolates collected from high resistance settings of Greek hospitals

(2021) Sachin S. Bhagwat et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Activity of Ceftazidime-Avibactam, Meropenem-Vaborbactam, and Imipenem-Relebactam against Carbapenemase-negative Carbapenem-resistant Enterobacterales (CRE) isolates from US Hospitals

(2021) Mariana Castanheira et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Susceptibility to Imipenem/Relebactam of Pseudomonas aeruginosa and Acinetobacter baumannii Isolates from Chinese Intra-Abdominal, Respiratory and Urinary Tract Infections: SMART 2015 to 2018

(2021) Hui Zhang et al.   Infection and Drug Resistance

Ceftolozane/tazobactam and imipenem/relebactam cross-susceptibility among clinical isolates of Pseudomonas aeruginosa from patients with respiratory tract infections in ICU and non-ICU wards – SMART United States 2017-2019

(2021) Sibylle H Lob et al.   Open Forum Infectious Diseases

Cefiderocol Activity Against Clinical Pseudomonas aeruginosa Isolates Exhibiting Ceftolozane-Tazobactam Resistance

(2021) Patricia J Simner et al.   Open Forum Infectious Diseases

Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital‐acquired/ventilator‐associated bacterial pneumonia

(2021) Munjal Patel et al.   CTS-Clinical and Translational Science

Activity of imipenem-relebactam and ceftolozane-tazobactam against carbapenem-resistant Pseudomonas aeruginosa and KPC-producing Enterobacterales

(2021) Larissa Bail et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa from patients hospitalized with pneumonia in European medical centers in 2020

(2021) Helio S. Sader et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Epidemiology and in vitro activity of ceftazidime–avibactam, meropenem–vaborbactam, imipenem–relebactam, eravacycline, plazomicin, and comparators against Greek carbapenemase-producing Klebsiella pneumoniae isolates

(2021) Sofia Maraki et al.   INFECTION

Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections

(2021) Helio S. Sader et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections

(2021) Nicholas Rebold et al.   Open Forum Infectious Diseases

Activity of imipenem-relebactam and meropenem-vaborbactam against carbapenem-resistant SME-producing Serratia marcescens

(2020) M Biagi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of imipenem/relebactam against carbapenem-resistant Escherichia coli isolates from the United States in relation to clonal background, resistance genes, co-resistance, and region

(2020) Brian D. Johnston et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A Comparison of Treatment Outcomes Between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem/Cilastatin/Relebactam Versus Colistin Plus Imipenem/Cilastatin in Patients With Imipenem-Nonsusceptible Bacterial Infections

(2020) Keith S. Kaye et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples – SMART Surveillance Europe 2015–2017

(2020) Sibylle H. Lob et al.   JOURNAL OF MEDICAL MICROBIOLOGY

Effect of Amoxicillin in combination with Imipenem-Relebactam against Mycobacterium abscessus

(2020) Rose C. Lopeman et al.   Scientific Reports

In Vitro Activity of the Ultra-Broad-Spectrum Beta-lactamase Inhibitor QPX7728 against Carbapenem-Resistant Enterobacterales (CRE) With Varying Intrinsic and Acquired Resistance Mechanisms

(2020) Kirk Nelson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam against Clinical Isolates of Gram-Negative Bacilli with Difficult-to-Treat Resistance and Multidrug-Resistant Phenotypes – SMART United States 2015-2017

(2020) James A Karlowsky et al.   CLINICAL INFECTIOUS DISEASES

A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)

(2020) Ivan Titov et al.   CLINICAL INFECTIOUS DISEASES

Activity of cefepime/zidebactam against MDR Escherichia coli isolates harbouring a novel mechanism of resistance based on four-amino-acid inserts in PBP3

(2020) Sachin S Bhagwat et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In Vitro Activity of WCK 5222 (Cefepime-Zidebactam) against Worldwide Collected Gram-Negative Bacilli Not Susceptible to Carbapenems

(2020) James A. Karlowsky et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Modifiable Risk Factors for the Emergence of Ceftolozane-Tazobactam Resistance

(2020) Pranita D Tamma et al.   CLINICAL INFECTIOUS DISEASES

Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired β-lactamases: 2020 update

(2020) Ester del Barrio-Tofiño et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

US Food and Drug Administration (FDA): Benefit-Risk Considerations for Cefiderocol (Fetroja®)

(2020) Shabnam Naseer et al.   CLINICAL INFECTIOUS DISEASES

In Vitro Activity of Imipenem/Relebactam Against Enterobacteriaceae Isolates Obtained from Intra-abdominal, Respiratory Tract, and Urinary Tract Infections in China: Study for Monitoring Antimicrobial Resistance Trends (SMART), 2015–2018

(2020) Qiwen Yang et al.   CLINICAL INFECTIOUS DISEASES

The safety and efficacy of relebactam/imipenem/cilastatin in Japanese patients with complicated intra-abdominal infection or complicated urinary tract infection: A multicenter, open-label, noncomparative phase 3 study

(2020) Shigeru Kohno et al.   JOURNAL OF INFECTION AND CHEMOTHERAPY

In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015–2016

(2019) Irene Galani et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Generating robust and informative nonclinical in vitro and in vivo bacterial infection model efficacy data to support translation to humans

(2019) Jürgen B. Bulitta et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IMI/REL versus P. aeruginosa from US SMART 2015–2017

(2019) James A. Karlowsky et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Antibacterial effect of imipenem/relebactam on aerobic Gram-negative bacilli: in vitro simulations of 7 or 14 day human exposures

(2019) Alan R Noel et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Activity of imipenem/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015–17

(2019) Sibylle H Lob et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Carbapenem Non-susceptible Pseudomonas aeruginosa from Intensive Care Units in the United States: A Potential Role for New β-lactam Combination Agents

(2019) Tomefa E Asempa et al.   JOURNAL OF CLINICAL MICROBIOLOGY

In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa

(2019) Katherine Young et al.   BMC MICROBIOLOGY

RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections

(2019) Johann Motsch et al.   CLINICAL INFECTIOUS DISEASES

A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam

(2019) Pratik Bhagunde et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Activity of imipenem/relebactam against carbapenemase-producing Enterobacteriaceae with high colistin resistance

(2019) Jessica Carpenter et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In-vitro activity of imipenem/relebactam and key β-lactam agents against Gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients – SMART Surveillance United States 2015–2017

(2019) James A. Karlowsky et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Impact of relebactam-mediated inhibition of Mycobacterium abscessus BlaMab β-lactamase on the in vitro and intracellular efficacy of imipenem

(2019) Eva Le Run et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In vitro activity of imipenem-relebactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples – SMART Surveillance United States 2015-2017

(2019) James A. Karlowsky et al.   Journal of Global Antimicrobial Resistance

Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilastatin

(2019) Pratik Bhagunde et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

In vivo Efficacy of Relebactam (MK-7655) in Combination with Imipenem/Cilastatin in Murine Infection Models

(2018) Mary Ann Powles et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clonal background, resistance gene profile, and porin gene mutations modulate in vitro susceptibility to imipenem/relebactam in diverse Enterobacteriaceae

(2018) Angela Gomez-Simmonds et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination With Imipenem and Cilastatin in Healthy Participants

(2018) Elizabeth G. Rhee et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activity of Imipenem-Relebactam against Clinical Isolates of Gram-Negative Bacilli Isolated in Hospital Laboratories in the United States as Part of the SMART 2016 Program

(2018) James A. Karlowsky et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Exploring the Pharmacokinetic/Pharmacodynamic Relationship of Relebactam (MK-7655) in Combination with Imipenem in a Hollow-Fiber Infection Model

(2018) Jin Wu et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects

(2018) Matthew L. Rizk et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme

(2018) James A Karlowsky et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Population pharmacokinetics and pharmacodynamics of bezlotoxumab in adults with primary and recurrent Clostridium difficile infection

(2018) Ka Lai Yee et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem

(2018) David C. Griffith et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Diversity of resistance mechanisms in carbapenem-resistant Enterobacteriaceae at a health care system in Northern California, from 2013 to 2016

(2018) Fiona Senchyna et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Pharmacokinetics and Pharmacodynamics of β-Lactamase Inhibitors

(2018) Ryan L. Crass et al.   PHARMACOTHERAPY

Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections

(2017) Matthew Sims et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection

(2016) Christopher Lucasti et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne bla KPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections

(2016) Ryan K. Shields et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City

(2015) Amabel Lapuebla et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection

(2015) Johanna Berkhout et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam

(2015) Renu Singh et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Pharmacodynamics of Imipenem in Combination with β-Lactamase Inhibitor MK7655 in a Murine Thigh Model

(2014) Eleftheria Mavridou et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®

(2014) Timothy A. Blizzard et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Novel Modeling Framework To Guide Design of Optimal Dosing Strategies for β-Lactamase Inhibitors

(2012) Pratik Bhagunde et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroActivity of MK-7655, a Novel β-Lactamase Inhibitor, in Combination with Imipenem against Carbapenem-Resistant Gram-Negative Bacteria

(2012) Elizabeth B. Hirsch et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY